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Objective: Thyroid peroxidase antibodies (TPOAbs) have been found to be related to the levels of thyroid
stimulating hormone (TSH) and to predict future development of thyroid failure in selected populations. We
investigated these relations in a euthyroid general population.
Design: Cross-sectional investigation of the relationship of TPOAbs and levels of TSH in euthyroid subjects.
Prospective investigation of the association of TPOAbs and TSH with development of hypothyroidism.
Incident hypothyroidism was deﬁned as initiation of L-thyroxine in the absence of thyreostatic medication.
Subjects: The study was performed in a random sample of 2703 participants of the PREVEND study. A total of
309 subjects were excluded from analyses, mainly because of TSH outside the reference range (0.35–
4.94 mIU/l; n=115).
Results: Mean (SD) baseline age was 47.7 (12.5) years, with 50.8% females. Prevalence of positive TPOAbs
(≥12 kU/l) was 8.4%. TSH concentrations were increased in subjects with TPOAbs (Pb0.001). During a
median follow-up of 9.1 years, 15 (0.6%) subjects developed hypothyroidism (3.5% in TPOAbs positive vs. 0.4%
in TPOAbs negative subjects; Pb0.001). Female sex (P=0.02), and TSH (Pb0.001) were also signiﬁcantly
associated with incident hypothyroidism. In multivariate analysis, TSH and TPOAbs remained independent
predictors (both Pb0.001).
Conclusions:We conﬁrmed the positive relationship of the presence of TPOAbs with levels of TSH and showed
that TPOAbs and TSH predict future development of hypothyroidism. These results are consistent with the
presence of TPOAbs necessitating a compensatory increase in levels of TSH for maintenance of euthyroidism,
even in the euthyroid range.
© 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Hypothyroidism, both overt and subclinical, is a common disorder,
with elevated levels of serum thyrotropin (TSH) in up to almost 10% of
the general population in prevalence studies [1–3]. Many of the
subjects in these studies were not aware of their thyroid dysfunction.
This high prevalence of undiagnosed thyroid dysfunction can have
important health consequences, since hypothyroidism is associated
with hypercholesterolemia [4], cardiovascular disease [5] and de-
pression [6].
With this knowledge, assessment of TSH is now a frequently
performed laboratory test. Abnormal thyroid function can be readily
diagnosed in this way. It would, however, also be of particular interest+31 50 3619069.
r).
ration of Internal Medicine. Publishif one could know which of currently euthyroid subjects are at
increased risk for development of thyroid dysfunction in the near
future. It is well known that higher prevalence rates of hypothyroid-
ism are found with advancing age and in women, particularly when
thyroid autoantibodies are present [1–3,7]. It has been suggested that
the presence of thyroid peroxidase antibodies may serve as a marker
of future thyroid failure [8]. Indeed, in a recent prospective study in a
selected population of females with high risk for development of
autoimmune thyroid disease, the presence of thyroid peroxidase
antibodies was identiﬁed as a risk factor for future thyroid failure [9].
Moreover, in the Whickham and Busselton studies it was found that
increasing values of serum TSH at baseline increased the probability of
developing hypothyroidism, and that this probability was further
increased when thyroid peroxidase antibodies were present [10,11].
In these studies, however, subjects with elevated levels of TSH at
baseline were not excluded. It is not established whether in the
euthyroid range the presence of thyroid peroxidase antibodies ised by Elsevier B.V. All rights reserved.
Table 1
Baseline characteristics (n=2394), according to TPOAbs status.
TPOAbs − TPOAbs + P value
N (%) 2193 (91.6) 201 (8.4)
Age (year) 47 (12) 50 (13) 0.006
Gender (females) 49% 72% b0.001
BMI (kg/m2) 25.8 (4.2) 26.6 (4.3) 0.02
Smoking (n/% yes) 914 (42) 75 (37) 0.21
TSH (mIU/l) 1.33 [0.96–1.84] 1.73 [1.22–2.56] b0.001
FT4 (pmol/l) 12.8±2.3 12.6±1.8 0.11
FT3 (nmol/l) 3.8±1.7 3.6±0.7 0.15
Data are given as mean (SD) or median [interquartile range].
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two prospective studies investigated the value of TSH and thyroid
peroxidase antibody titers in subjects with normal levels of TSH
[12,13]. In these studies, however, the presence of elevated TSH levels
during follow-up was assessed by screening. Screening for hypothy-
roidism is, however, not part of current clinical practice. The value of
the presence of thyroid peroxidase antibodies as a risk factor for
future development of clinical thyroid failure in currently euthyroid
subjects of the general population remains therefore to be established.
Our aim was to investigate, in an unselected sample of euthyroid
subjects within the general population, the relationship of the
presence of thyroid peroxidase antibodies (TPOAbs) with the levels
of TSH within the normal reference range. We also aimed to
prospectively investigate whether the presence of TPOAbs and levels
of TSH predict incident clinical hypothyroidism – deﬁned as
prescription of L-thyroxine by a general practitioner or internist —
in the same euthyroid subjects.
2. Methods
2.1. Study population and design
The database used for this study consisted of a random sample of
2703 participants of the PREVEND (Prevention of REnal and Vascular
ENd stage Disease) study, all inhabitants, aged 28 to 75 years, of the
city of Groningen, a middle-sized city in the northern part of the
Netherlands. Pregnant women were excluded from this study. The
protocol of the PREVEND study has been described elsewhere [14]. In
short, this study prospectively investigates the natural course of renal
and cardiovascular disease in a large cohort drawn from the general
population.
At baseline, bloodwas drawn to assess thyroid function and TPOAbs
status, after which subjects were prospectively followed. TPOAbs were
considered positive when ≥12 kU/l, which is the cut-off point
recommended by the manufacturer of the assay (Abbott Laboratories,
Abbott Park, IL 60064, USA; kit number 5F57). For our analyses, we only
studied euthyroid subjects according to a TSH level within our
laboratory's reference range (0.35–4.94 mIU/l). We excluded a total
number of 309 subjects: those with – at baseline – a TSH above the
laboratory's reference range (n=52) and those with – at baseline – a
TSH below the laboratory's reference range (n=63), as well as subjects
of whom TPOAbs status was missing (n=4). Subjects of whom no
follow-up of pharmacy data (with information about prescription of
drugs, including thyroid medication) was available (n=92) were also
excluded. We further excluded subjects who were taking thyroid
medication (both L-thyroxine and thyrostatic drugs; n=37) and/or
medications that may affect thyroid function tests at baseline (namely
oral glucocorticoids, lithium and/or amiodarone [15]; n=56). Subjects
that developed hyperthyroidism during follow-up were also excluded
from analyses (n=5), leaving 2394 subjects eligible for analyses.
The Netherlands is considered to be a country with a sufﬁcient intake
of dietary iodine, with a median urinary iodine excretion level of
154 μg/l [16].
The study was approved by the local medical ethical committee.
All participants gave written informed consent.
2.2. Assays and measurements
Serum sampleswere stored at−20 °C until analysis. Serum TSHwas
assessed using amicroparticle enzyme immunoassay (Architect, Abbott
Laboratories, Abbott Park, IL 60064, USA). FT4 and FT3 concentrations
were also assessed using a microparticle enzyme immunoassay
(AxSYM, Abbott Laboratories, Abbott Park, IL 60064, USA). Serum
thyroperoxidase antibodies (TPOAbs) were assessed using a micropar-
ticle enzyme immunoassay (AxSYM) for the quantitative measurement
of immunoglobulin G (IgG) class antibodies.Body Mass Index (BMI) was calculated as body weight (kilogram)
divided by the square of body height (meter).
2.3. Deﬁnition of incident hypothyroidism
Incident hypothyroidism was deﬁned as initiation of L-thyroxine
therapy in the absence of thyreostatic medication. The practice
guidelines ‘Thyroid disorders’ from the Dutch College of General
Practitioners and The Netherlands Association of Internal Medicine
recommend start of treatment for hypothyroidism if TSH exceeds
12 mIU/l [17,18]. It is not recommended to treat subjects with
TSH≤12 mIU/l, which is considered subclinical hypothyroidism.
Dutch physicians adhere well to these guidelines [19]. The PREVEND
participants were asked at which pharmacy they collected their
prescription medication. At baseline and during follow-up, pharmacy
records were collected at community pharmacies. Because Dutch
patients usually register at a single community pharmacy, use of
pharmacy records provides an individual listing of prescribed drugs
for each PREVEND participant [20,21]. The pharmacy data contain,
among others, the name of the drug, number of units dispensed,
prescribed daily dose, the date the drugs were obtained, and
Anatomical Therapeutical Chemical classiﬁcation code of the drug.
2.4. Statistical analysis
SPSS 12 (SPSS, Inc., Chicago, IL) and Excel (Microsoft Corp.,
Redmond, WA) were used for data analysis. Data are expressed as
mean (SD) or median [interquartile range] when appropriate.
Statistical comparisons were performed by means of independent-
sample t tests for data with a normal distribution, Mann–Whitney U
tests for data with a skewed distribution and Chi-square tests for
percentages. Logistic regression analyses were performed for assess-
ment of associations of TPOAbs status with age and TSH. Cox-
regression analyses were performed for assessment of associations of
age, sex, smoking, thyroid function parameters and log-transformed
TPOAbs with incidence of hypothyroidism, both univariately and
multivariately. Variables retained in the ﬁnal multivariate model were
selected by a stepwise backward procedure. P valuesb0.05 were
considered to indicate statistical signiﬁcance.
3. Results
3.1. Baseline characteristics
Population characteristics according to TPOAbs status are shown in
Table 1. Median [interquartile range] TPOAbs titer in TPOAbs positive
subjects was 85 [31-243] kU/l. Age, percentage of females, TSH and
BMI were signiﬁcantly higher in TPOAbs positive subjects compared
to TPOAbs negative subjects.
Prevalence of positive TPOAbs was 8.4% (11.9% vs. 4.8% for females
andmales respectively; Pb0.001). This percentage increased with age
(P=0.006), with highest prevalence (18.7%) in women aged 60–
69 years. The prevalence of positive TPOAbs according to quartiles of
Fig. 2. Kaplan–Meier plot for incidence of hypothyroidism according to TSH.
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TSH in the euthyroid range (Pb0.001, Fig. 1). Median [interquartile
range] TSH for TPOAbs positive subjects was 1.73 [1.22–2.56]mIU/l,
compared to 1.33 [0.96–1.84]mIU/l in TPOAbs negative subjects
(Pb0.001).
3.2. Relationship of positive TPOAbs and future thyroid dysfunction
Median [interquartile range] follow-up was 9.1 [9.0–9.2] years.
During follow-up, incidence of hypothyroidism was much lower in
subjects in the lowest quartiles of TSH than those in the highest
quartile (1 (0.2%), 2 (0.3%), 2 (0.3%) and 10 (1.7%) respectively,
Pb0.001). A Kaplan–Meier plot for the lowest three quartiles vs. the
highest quartile is shown in Fig. 2. Incidence of hypothyroidism was
signiﬁcantly lower in TPOAbs negative subjects than in TPOAbs
positive subjects: 8 out of 2193 TPOAb negative subjects vs. 7 out of
201 TPOAb positive subjects started L-thyroxine (0.4% vs. 3.5%;
Pb0.001). A Kaplan–Meier plot of the respective incidences is
shown in Fig. 3.
Results of univariate and multivariate Cox-regression analyses are
shown in Table 2. In univariate analyses, female sex appeared also
predictive of development of hypothyroidism, in addition to TSH and
TPOAbs. The association of FT4 was borderline signiﬁcant. In
subsequent multivariate analyses, only TSH and TPOAbs remained
as signiﬁcant independent predictors of incident hypothyroidism.
4. Discussion
We found a cross-sectional positive association between the
presence of TPOAbs and the levels of TSH within the euthyroid
range. These results are consistent with the presence of TPOAbs
necessitating a compensatory increase in levels of TSH for mainte-
nance of euthyroidism, even in the euthyroid range. We also found
that TSH and TPOAbs predict development of hypothyroidism in a
general population of subjects with all normal levels of TSH at
baseline. Incidence of hypothyroidism during 9 years of follow-up
was signiﬁcantly higher in subjects with positive TPOAbs at baseline
compared to TPOAbs negative subjects. We demonstrated that both
TPOAbs and TSH level are independent predictors of hypothyroidism,
even in subjects with a TSH level within the normal laboratory's
reference range.
We found a cross-sectional association between the presence of
TPOAbs and increasing levels of TSH within the euthyroid range. This
ﬁnding, in combination with the presence of TPOAbs and the levels ofFig. 1. Prevalence of positive TPOAbs for quartiles of TSH within the normal reference
range (n=2394). TSH ranged from 0.35 to 0.97 mIU/l in quartile 1, from 0.97 to 1.36 in
quartile 2, from 1.36 to 1.89 in quartile 3 and from 1.89 to 4.85 in quartile 4.TSH as independent predictors of future development of thyroid
failure, strongly suggests that TSH levels – even though they are still in
what is considered the normal range – in subjects with TPOAbs would
have been lower if they would not have had TPOAbs. Apparently, the
presence of TPOAbs frequently sets a subject in a compensated state in
which somewhat higher levels of TSH – although still in the reference
range – are necessary for the thyroid to produce enough thyroid
hormone to maintain euthyroidism. This ﬁnding is consistent with
earlier studies by Jensen et al. and Hollowell et al., where the presence
of TPOAbs was not only found to be associated with a higher
frequency of levels of TSH outside the reference range, but also with a
tendency for higher levels of TSH within the reference range [2,22].
Our ﬁndings ﬁt well with results of a recently published pro-
spective study in a high risk population of female relatives of patients
with autoimmune thyroid disease, in which the presence of TPOAbs
and high normal levels of TSH levels were found to predict future
development of overt thyroid disease [9]. Our prospective study
conﬁrms the importance of TPOAbs as a marker for future thyroid
disease and extends it to the general population. To the best of our
knowledge, only two earlier prospective studies investigated the
value of TSH and TPOAb titers in subjects with normal levels of TSH
[12,13]. One study, however, only included middle-aged women and
the other was performed in an area in which mild iodine deﬁciency is
very common. Iodine deﬁciency is virtually absent in the Netherlands
[16]. Other studies were performed in subjects with established
subclinical hypothyroidism and demonstrated the predictive value of
thyroid antibodies for development of overt hypothyroidism in these
subjects [23,24]. In the Whickham and Busselton studies it was found
that increasing values of serum TSH at ﬁrst survey increased theFig. 3. Kaplan–Meier plot for incidence of hypothyroidism according to TPO status.
Table 2
Univariate and multivariate Cox-regression analyses for determinants of incident
hypothyroidism.
Univariate analyses Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 0.98 0.65–1.47 0.93 – – –
Sex 6.33 1.43–28.03 0.02 – – –
Current smoking 0.71 0.24–2.07 0.52 – – –
Ex-smoking 0.83 0.27–2.61 0.75 – – –
TSH 3.19 2.09–4.88 b0.001 2.41 1.53–3.79 b0.001
FT4 0.78 0.58–1.03 0.08 – – –
FT3 0.92 0.47–1.81 0.80 – – –
log TPOAbs 3.84 2.40–6.15 b0.001 2.87 1.67–4.90 b0.001
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was further increased when TPOAbs were present [10,11]. In these
studies, however, subjects with elevated levels of TSH at baseline
were not excluded. Our results extend the ﬁndings of these studies
with the notion that even variation of levels of TSH within what is
considered the normal range is important for prediction of develop-
ment of hypothyroidism.
The pathophysiologic process behind the relationship of TPOAbs
prevalence and future thyroid disease is complex and not completely
understood [25]. Thyroid peroxidase (TPO) is not only known to be the
primary enzyme in the synthesis of thyroid hormone, it also serves as a
major autoantigen [26]. Moreover, it has been hypothesized that
TPOAbs should not be viewed as one entity since their pathogenic
potential might be inﬂuenced depending on which epitope of TPO they
are binding to [27]. The presence of TPOAbs is characteristic for
autoimmune thyroid diseases [28], both in hypothyroidism (Hashimo-
to's thyroiditis) and (Graves') hyperthyroidism. The cause of Hashimo-
to's thyroiditis is thought to be a combination of genetic susceptibility
and environmental factors [7]. The antibodies aremainly produced by a
lymphocytic inﬁltrate in the thyroid gland [29], with a signiﬁcant
correlation between the degree of this lymphocytic inﬁltration and the
titer of microsomal antibodies [30]. In combination with the demon-
strated higher prevalence of positive TPOAbs with increasing TSH
concentrations, even in euthyroidism, the presence of TPOAbs can thus
be regarded as a marker for increased risk of future thyroid failure.
In recent years there have been considerable discussion and
disagreement regarding the upper normal TSH concentration [31,32].
Subclinical hypothyroidism, an elevated serum TSH level in combina-
tion with normal FT4 concentrations, has been found to be associated
with ischemic heart disease [33,34]. However, randomized controlled
trials that show that levothyroxine replacement therapy for subclinical
hypothyroidism results in improved survival or decreased cardiovas-
cular morbidity are lacking [35]. Thus, the relevance of our ﬁndings
from the perspective of cardiovascular protection has not yet been
established. From the perspective of health care, however, it is very
relevant. Hypothyroidism is a prevalent disorder, which develops
slowly, and acknowledgment of symptoms is frequently difﬁcult.
Therefore, many guidelines advise screening of subjects in case of
vague complaints [36]. Moreover, aggressive case ﬁnding is recom-
mended in pregnant women, women older than 60 years, and others at
high risk for thyroid dysfunction, although consensus about screening
strategies is lacking [36,37]. It is not known for how long a normal TSH
can be trusted as certiﬁcation of sustained euthyroidism. Our results
suggest that sustainability of a normal TSH is much higher in people
with TSH in the lower range of normal concentrations and in people
with the absence of TPOAbs. Future studieswill have to be performed to
designate more detailed screening strategies.
There are some limitations to our study. We have underestimated
incidence of hypothyroidism since no repeated measurements of all
subjects in our study were performed. Indeed, incidence of hypothy-
roidism in our study (0.015%/year) was much lower than incidencefound in a large Dutch study among general practitioners (0.12%/year)
[38] and in the earlier mentioned other follow-up studies [12,13].
Instead, incident hypothyroidism was deﬁned as prescription of L-
thyroxine by general practitioners and internists. These physicians
were unaware of baseline laboratory results. Therefore, only subjects
who visited their doctor with complaints were detected. Currently, in
many countries no routine screening programs for thyroid function
testing are running. For this reason, however, our study is in keeping
with the daily practice of general practitioners and internists and
presents the relevance of knowledge of results of an assay for TPOAbs
for clinical practice. However, this is more likely to result in under-
appreciation of the effects of TPOAbs and levels of TSH as predictors of
development of thyroid failure rather than overappreciation. An
important strength of our study is the availability of pharmacy data,
which is a highly reliable measure of prescribed drugs [20,21], which
also allowed us to perform time-to-event analyses for development of
thyroid failure.
In conclusion, in a cross-sectional study we demonstrated a relation
of the presence of TPOAbs with the levels of TSH within the euthyroid
range. This is highly suggestive of the presence of TPOAbs to necessitate
a compensatory increase in the levels of TSH for maintenance of
euthyroidism. Moreover, in euthyroid subjects in a general population
we have demonstrated that TPOAbs level and TSH level are both
independent predictors for future hypothyroidism, even when TSH is
still within the laboratory reference range. Although our results need to
be conﬁrmed in studies with repeated measurements of thyroid status,
our results strongly suggest that TPOAbs and levels of TSH can be used
as a tool for identifying subjects at risk for developing overt hypo-
thyroidism in the general population.
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Learning points
• There is a positive relationship of the presence of TPOAbs with the
levels of TSH, even in the euthyroid range.
• Both TPOAbs and TSH independently predict future development of
hypothyroidism, even in the euthyroid range.References
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